<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H9F3D6B1179F545E6812AB2338F2F257F" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 413 IH: To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-01-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 413</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130123">January 23, 2013</action-date>
			<action-desc><sponsor name-id="W000800">Mr. Welch</sponsor> (for
			 himself, <cosponsor name-id="H001051">Mr. Hanna</cosponsor>,
			 <cosponsor name-id="C000754">Mr. Cooper</cosponsor>, and
			 <cosponsor name-id="B001259">Mr. Braley of Iowa</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in
			 addition to the Committee on <committee-name committee-id="HWM00">Ways and
			 Means</committee-name>, for a period to be subsequently determined by the
			 Speaker, in each case for consideration of such provisions as fall within the
			 jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To eliminate the 2-year delay in including oral-only
		  ESRD-related drugs in the Medicare ESRD prospective payment system, as provided
		  under section 632(b)(1) of the American Taxpayer Relief Act of
		  2012.</official-title>
	</form>
	<legis-body id="HCA8829018FEF43B8B32D5170DF6FAB93" style="OLC">
		<section id="HF86720E777AE46AE935853736162E738" section-type="section-one"><enum>1.</enum><header>Eliminating the 2-year delay
			 in implementation of oral-only ESRD-related drugs in the Medicare ESRD
			 prospective payment system</header><text display-inline="no-display-inline">Section 632(b) of the American Taxpayer
			 Relief Act of 2012 (<external-xref legal-doc="public-law" parsable-cite="pl/112/240">Public Law 112â€“240</external-xref>) is amended by striking all that
			 precedes <quote>With respect to the implementation</quote> and inserting the
			 following::</text>
			<quoted-block display-inline="no-display-inline" id="HE0E15A7D6B7F4F8DB07645510F2A9A17" style="OLC">
				<subsection id="H068E43C1D0C541BAA12BBB198AC5C31C"><enum>(b)</enum><header>Monitoring of
				implementation of oral-Only ESRD-Related drugs in the ESRD prospective payment
				system</header><text display-inline="yes-display-inline">With respect to the
				implementation</text>
				</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


